Home >> Pharmaceuticals >> Food & Beverage >>

Noxxon Pharma AG - Product Pipeline Review - 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 36 | Code: MRS - 35152

Noxxon Pharma AG - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Noxxon Pharma AG - Product Pipeline Review - 2015’, provides an overview of the Noxxon Pharma AG’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Noxxon Pharma AG’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Noxxon Pharma AG including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Noxxon Pharma AG’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Noxxon Pharma AG’s pipeline products

Reasons to buy

- Evaluate Noxxon Pharma AG’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Noxxon Pharma AG in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Noxxon Pharma AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Noxxon Pharma AG and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Noxxon Pharma AG
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Noxxon Pharma AG and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Noxxon Pharma AG Snapshot 5
Noxxon Pharma AG Overview 5
Key Information 5
Key Facts 5
Noxxon Pharma AG - Research and Development Overview 6
Key Therapeutic Areas 6
Noxxon Pharma AG - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Noxxon Pharma AG - Pipeline Products Glance 10
Noxxon Pharma AG - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Noxxon Pharma AG - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Noxxon Pharma AG - Drug Profiles 12
emapticap pegol 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
lexaptepid pegol 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
olaptesed pegol 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
NOXD-19 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
NOXD-20 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
NOXG-15 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NOXG-16 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
NOXL-41 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
NOXS-93 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Noxxon Pharma AG - Pipeline Analysis 25
Noxxon Pharma AG - Pipeline Products by Target 25
Noxxon Pharma AG - Pipeline Products by Route of Administration 26
Noxxon Pharma AG - Pipeline Products by Molecule Type 27
Noxxon Pharma AG - Pipeline Products by Mechanism of Action 28
Noxxon Pharma AG - Recent Pipeline Updates 29
Noxxon Pharma AG - Dormant Projects 33
Noxxon Pharma AG - Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 35
Contact Us 35
Disclaimer 36

List of Tables
Noxxon Pharma AG, Key Information 5
Noxxon Pharma AG, Key Facts 5
Noxxon Pharma AG - Pipeline by Indication, 2015 7
Noxxon Pharma AG - Pipeline by Stage of Development, 2015 8
Noxxon Pharma AG - Monotherapy Products in Pipeline, 2015 9
Noxxon Pharma AG - Phase II, 2015 10
Noxxon Pharma AG - Preclinical, 2015 11
Noxxon Pharma AG - Pipeline by Target, 2015 25
Noxxon Pharma AG - Pipeline by Route of Administration, 2015 26
Noxxon Pharma AG - Pipeline by Molecule Type, 2015 27
Noxxon Pharma AG - Pipeline Products by Mechanism of Action, 2015 28
Noxxon Pharma AG - Recent Pipeline Updates, 2015 29
Noxxon Pharma AG - Dormant Developmental Projects,2015 33
Noxxon Pharma AG, Subsidiaries 34

List of Figures
Noxxon Pharma AG - Pipeline by Top 10 Indication, 2015 7
Noxxon Pharma AG - Pipeline by Stage of Development, 2015 8
Noxxon Pharma AG - Monotherapy Products in Pipeline, 2015 9
Noxxon Pharma AG - Pipeline by Top 10 Target, 2015 25
Noxxon Pharma AG - Pipeline by Top 10 Route of Administration, 2015 26
Noxxon Pharma AG - Pipeline by Top 10 Molecule Type, 2015 27
Noxxon Pharma AG - Pipeline Products by Top 10 Mechanism of Action, 2015 28

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

Single User | $(USD)1500 View Pricing